PD3-3-1: A phase Ib/randomized phase II, non-comparative, open label trial of paclitaxel and carboplatin with or without the anti-IGF-IR antibody CP-751,871 as first-line treatment for advanced non-small cell lung cancer (NSCLC)
Karp, Daniel D., Paz-Ares, L.G., Pollak, M.N., Eisenberg, P.D., Blakely, L.J., Haluska, P, Cohen, R.B., Kreisman, H, Melvin, C.L., Gualberto, AVolume:
2
Language:
english
Journal:
Journal of Thoracic Oncology
DOI:
10.1097/01.JTO.0000283411.38367.97
Date:
August, 2007
File:
PDF, 165 KB
english, 2007